Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy

Yasutomo Nasu, Takashi Saika, Shin Ebara, Nobuyuki Kusaka, Haruki Kaku, Fernando Abarzua, Daisuke Manabe, Timothy C. Thompson, Hiromi Kumon

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as the first prostate cancer gene therapy trial. Major inclusion criteria were local recurrence of prostate cancer after hormonal therapy and no metastasis. Adv.HSV-tk was injected directly into the prostate in escalating doses from 109 to 1010 infection units, followed by intravenous administration of GCV for 14 days. Eight patients received nine courses of this gene therapy. The detection of vector DNA in blood/urine was only transient and no remarkable adverse events were observed in any patient. With regard to clinical response, significant prolongation of the median serum prostate-specific antigen (PSA) doubling time from 2.9 to 6.2 months (P = 0.041) was detected. In five patients (six injections), a clear decrease of PSA values was observed. One patient showed repeated clinical response after repeated injections. Serum cytokine analysis showed no notable changes after treatment. Fluorescence-activated cell sorting analysis also showed no influence on phenotypic distribution in peripheral blood samples, except for an increasing trend of CD8+/HLA-DR+ after therapy. This study confirmed the safety profile and possibility of clinical response at the surrogate marker level in a clinical trial of HSV-tk gene therapy for hormone-refractory prostate cancer.

Original languageEnglish
Pages (from-to)834-840
Number of pages7
JournalMolecular Therapy
Volume15
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Genetic Therapy
Suicide
Thymidine Kinase
Prostatic Neoplasms
Simplexvirus
Recurrence
Ganciclovir
Prostate-Specific Antigen
Genes
Injections
Neoplasm Genes
HLA-DR Antigens
Therapeutics
Serum
Intravenous Administration
Prostate
Flow Cytometry
Biomarkers
Clinical Trials
Urine

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. / Nasu, Yasutomo; Saika, Takashi; Ebara, Shin; Kusaka, Nobuyuki; Kaku, Haruki; Abarzua, Fernando; Manabe, Daisuke; Thompson, Timothy C.; Kumon, Hiromi.

In: Molecular Therapy, Vol. 15, No. 4, 04.2007, p. 834-840.

Research output: Contribution to journalArticle

Nasu, Yasutomo ; Saika, Takashi ; Ebara, Shin ; Kusaka, Nobuyuki ; Kaku, Haruki ; Abarzua, Fernando ; Manabe, Daisuke ; Thompson, Timothy C. ; Kumon, Hiromi. / Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. In: Molecular Therapy. 2007 ; Vol. 15, No. 4. pp. 834-840.
@article{52c07c702229463da0bb3e98473f8e31,
title = "Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy",
abstract = "We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as the first prostate cancer gene therapy trial. Major inclusion criteria were local recurrence of prostate cancer after hormonal therapy and no metastasis. Adv.HSV-tk was injected directly into the prostate in escalating doses from 109 to 1010 infection units, followed by intravenous administration of GCV for 14 days. Eight patients received nine courses of this gene therapy. The detection of vector DNA in blood/urine was only transient and no remarkable adverse events were observed in any patient. With regard to clinical response, significant prolongation of the median serum prostate-specific antigen (PSA) doubling time from 2.9 to 6.2 months (P = 0.041) was detected. In five patients (six injections), a clear decrease of PSA values was observed. One patient showed repeated clinical response after repeated injections. Serum cytokine analysis showed no notable changes after treatment. Fluorescence-activated cell sorting analysis also showed no influence on phenotypic distribution in peripheral blood samples, except for an increasing trend of CD8+/HLA-DR+ after therapy. This study confirmed the safety profile and possibility of clinical response at the surrogate marker level in a clinical trial of HSV-tk gene therapy for hormone-refractory prostate cancer.",
author = "Yasutomo Nasu and Takashi Saika and Shin Ebara and Nobuyuki Kusaka and Haruki Kaku and Fernando Abarzua and Daisuke Manabe and Thompson, {Timothy C.} and Hiromi Kumon",
year = "2007",
month = "4",
doi = "10.1038/sj.mt.6300096",
language = "English",
volume = "15",
pages = "834--840",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy

AU - Nasu, Yasutomo

AU - Saika, Takashi

AU - Ebara, Shin

AU - Kusaka, Nobuyuki

AU - Kaku, Haruki

AU - Abarzua, Fernando

AU - Manabe, Daisuke

AU - Thompson, Timothy C.

AU - Kumon, Hiromi

PY - 2007/4

Y1 - 2007/4

N2 - We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as the first prostate cancer gene therapy trial. Major inclusion criteria were local recurrence of prostate cancer after hormonal therapy and no metastasis. Adv.HSV-tk was injected directly into the prostate in escalating doses from 109 to 1010 infection units, followed by intravenous administration of GCV for 14 days. Eight patients received nine courses of this gene therapy. The detection of vector DNA in blood/urine was only transient and no remarkable adverse events were observed in any patient. With regard to clinical response, significant prolongation of the median serum prostate-specific antigen (PSA) doubling time from 2.9 to 6.2 months (P = 0.041) was detected. In five patients (six injections), a clear decrease of PSA values was observed. One patient showed repeated clinical response after repeated injections. Serum cytokine analysis showed no notable changes after treatment. Fluorescence-activated cell sorting analysis also showed no influence on phenotypic distribution in peripheral blood samples, except for an increasing trend of CD8+/HLA-DR+ after therapy. This study confirmed the safety profile and possibility of clinical response at the surrogate marker level in a clinical trial of HSV-tk gene therapy for hormone-refractory prostate cancer.

AB - We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as the first prostate cancer gene therapy trial. Major inclusion criteria were local recurrence of prostate cancer after hormonal therapy and no metastasis. Adv.HSV-tk was injected directly into the prostate in escalating doses from 109 to 1010 infection units, followed by intravenous administration of GCV for 14 days. Eight patients received nine courses of this gene therapy. The detection of vector DNA in blood/urine was only transient and no remarkable adverse events were observed in any patient. With regard to clinical response, significant prolongation of the median serum prostate-specific antigen (PSA) doubling time from 2.9 to 6.2 months (P = 0.041) was detected. In five patients (six injections), a clear decrease of PSA values was observed. One patient showed repeated clinical response after repeated injections. Serum cytokine analysis showed no notable changes after treatment. Fluorescence-activated cell sorting analysis also showed no influence on phenotypic distribution in peripheral blood samples, except for an increasing trend of CD8+/HLA-DR+ after therapy. This study confirmed the safety profile and possibility of clinical response at the surrogate marker level in a clinical trial of HSV-tk gene therapy for hormone-refractory prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33947279386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947279386&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300096

DO - 10.1038/sj.mt.6300096

M3 - Article

C2 - 17327829

AN - SCOPUS:33947279386

VL - 15

SP - 834

EP - 840

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -